Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index; 57 of the 135 sources its claims cite were checked for support.
Abstract
The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-onset dementia. The diagnosis of bvFTD remains challenging because of the limited accuracy of neuroimaging in the early disease stages and the absence of molecular biomarkers, and therefore relies predominantly on clinical assessment. BvFTD shows significant symptomatic overlap with non-degenerative primary psychiatric disorders including major depressive disorder, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorders and even personality disorders. To date, ∼50% of patients with bvFTD receive a prior psychiatric diagnosis, and average diagnostic delay is up to 5-6 years from symptom onset. It is also not uncommon for patients with primary psychiatric disorders to be wrongly diagnosed with bvFTD. The Neuropsychiatric International Consortium for Frontotemporal Dementia was recently established to determine the current best clinical practice and set up an international collaboration to share a common dataset for future research. The goal of the present paper was to review the existing literature on the diagnosis of bvFTD and its differential diagnosis with primary psychiatric disorders to provide consensus recommendations on the clinical assessment. A systematic literature search with a narrative review was performed to determine all bvFTD-related diagnostic evidence for the following topics: bvFTD history taking, psychiatric assessment, clinical scales, physical and neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural neuroimaging, functional neuroimaging, CSF and genetic testing. For each topic, responsible team members proposed a set of minimal requirements, optimal clinical recommendations, and tools requiring further research or those that should be developed. Recommendations were listed if they reached a ≥ 85% expert consensus based on an online survey among all consortium participants. New recommendations include performing at least one formal social cognition test in the standard neuropsychological battery for bvFTD. We emphasize the importance of 3D-T1 brain MRI with a standardized review protocol including validated visual atrophy rating scales, and to consider volumetric analyses if available. We clarify the role of 18F-fluorodeoxyglucose PET for the exclusion of bvFTD when normal, whereas non-specific regional metabolism abnormalities should not be over-interpreted in the case of a psychiatric differential diagnosis. We highlight the potential role of serum or CSF neurofilament light chain to differentiate bvFTD from primary psychiatric disorders. Finally, based on the increasing literature and clinical experience, the consortium determined that screening for C9orf72 mutation should be performed in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
Overview
CoChat Summary
TL;DR
This consensus review from the Neuropsychiatric International Consortium for Frontotemporal Dementia summarizes evidence and expert recommendations for distinguishing behavioural variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPD). It recommends formal social cognition testing, standardized 3D-T1 MRI review, cautious FDG-PET interpretation, consideration of neurofilament light chain, and C9orf72 screening in possible/probable bvFTD or suspected cases with strong psychiatric features.
Key findings
- bvFTD is frequently misdiagnosed: around 50% of patients receive a prior psychiatric diagnosis, average diagnostic delay is up to 5–6 years from symptom onset, possible bvFTD criteria had poor specificity (27%) in a mixed neuropsychiatric cohort, standard MRI sensitivity was 70%, and FDG-PET specificity was 68% because of frequent non-specific abnormalities in PPD.
- New or emphasized recommendations include at least one formal social cognition test in the standard neuropsychological battery for bvFTD; 3D-T1 brain MRI with a standardized review protocol and validated visual atrophy rating scales, considering volumetric analyses if available; FDG-PET to support exclusion when normal, while non-specific regional hypometabolism should not be over-interpreted in a psychiatric differential diagnosis; consideration of serum or CSF neurofilament light chain (NfL) where reference values are available; and C9orf72 screening in all possible/probable bvFTD cases or suspected cases with strong psychiatric features.
- Biomarker evidence cited: CSF NfL discriminated bvFTD from PPD with an AUC of 0.93 in a study of 22 bvFTD and 25 PPD patients; plasma NfL showed AUCs of 0.89–0.94 against schizophrenia, depression, and bipolar disorder, and 0.83 in a larger study of 66 bvFTD and 34 PPD patients; CSF NfL discriminated FTD mutation carriers from controls with an AUC of 0.99.
- Clinical scales and cognitive tests have mixed utility: the Frontal Behavioral Inventory overall score does not distinguish bvFTD from PPD, but a positive FBI subscale score >12 was indicative of bvFTD in late-onset behavioural changes; MMSE was unsuccessful for discrimination; MoCA had 88% classification accuracy for brief cognitive screening but uncertain value against PPD; the Institute of Cognitive Neurology Frontal Screening may have discriminatory power; and a meta-analysis indicated social cognition impairment in bvFTD is more severe than in major psychiatric and developmental disorders.
Methods
- Systematic literature search in Medline (PubMed) and Embase, completed September 2017, retrieving articles from 1992 to 2017, with relevant later references allowed; topics included bvFTD history taking, psychiatric assessment, clinical scales, physical/neurological examination, bedside cognitive tests, neuropsychological assessment, social cognition, structural and functional neuroimaging, CSF, and genetic testing.
- Each topic was assigned to two to three NIC-FTD members based on expertise; teams reviewed abstracts and proposed minimal requirements, clinical recommendations, and tools requiring further research; an in-person meeting was held in Sydney on 13 November 2018, followed by two rounds of draft review and teleconferences.
- Final consensus was obtained through an online survey of all co-authors, with ≥85% approval required to include recommendations.
Limitations
- The paper states that diagnostic methods useful for distinguishing bvFTD from other dementias, such as clinical scales and cognitive tests, do not fare as well against PPD; some patients remain diagnostically ambiguous despite optimal clinical investigation, so longitudinal follow-up often becomes the diagnostic arbiter until pathology is available; non-progressive bvFTD phenocopy cases are particularly challenging, with small sample studies and some showing no FTLD pathological changes.
- The paper states a need for better prognostic tools; CSF biomarkers require study in larger, ideally pathologically and/or genetically confirmed bvFTD cohorts; volumetric and machine-learning MRI methods lack replication and prospective validation at the individual subject level; and many social cognition instruments lack normative data and transcultural adaptation.
- Evident from the text: the recommendations are consensus-based (≥85% expert approval) rather than prospectively validated, and many cited diagnostic accuracy estimates come from small or single studies; the systematic search ended in September 2017, with later references added non-systematically.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Valid · 11 Not valid · 43 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients with FTD secondary to the C9orf72 mutation can present with heterogeneous neuropsychiatric phenotypes (such as lateonset psychosis or mania) without family history, sometimes several years prior to onset of more typical bvFTD features (Ducharme et al. , 2017).”
What the sources say
- Supportedcites Ducharme et al., 2017 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Mild Behavioral Impairment Checklist is a more specific tool to measure later-life behavioural changes that can be the harbinger of dementia (Ismail et al. , 2017); however, it does not facilitate the differentiation of PPD from bvFTD.”
What the sources say
- Supportedcites Ismail et al., 2017 source
The citation is attached to the first clause, which describes the MBI-C as a tool for measuring later-life behavioural changes that may precede dementia. The Discussion says it was created to measure behavioural changes in older adults that might precede dementia. The subsequent statement about differentiating PPD from bvFTD is not attributed to this source by the citation placement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“DAPHNE, a recently developed informant-based behavioural inventory with 10 items based on the 2011 bvFTD international consensus diagnostic criteria, demonstrated an ability to distinguish bvFTD from bipolar disorder (Boutoleau-Bretonniere et al. , 2015).”
What the sources say
- Supportedcites Boutoleau-Bretonniere et al., 2015 source
The Results (Validation of the DAPHNE Scale; page not provided) state that DAPHNE differentiated bvFTD from the comparison groups, including patients with bipolar disorder. The Abstract (Objective) describes a ten-item inventory adapted from Rascovsky’s criteria, and the Methods describe its administration to caregivers. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“On the IFS, however, patients with bvFTD scored significantly worse on several sub-items than subjects with major depression and bipolar disorder (Fiorentino et al. , 2013).”
What the sources say
- Partly supportedcites Fiorentino et al., 2013 sourceExperimental — accuracy not yet measured
The Results report significantly lower bv-FTD scores than depression scores on five IFS subtests. The Methods identify the comparison group as patients with unipolar depression; the cited study does not support the claim about bipolar disorder. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Major consensus dementia investigation guidelines all recommend structural brain imaging as part of the investigation of bvFTD (Knopman et al. , 2001; Filippi et al. , 2012; Soucy et al. , 2013).”
What the sources say
- Not checked — no full text of the sourcecites Knopman et al. , 2001 source
- Supportedcites Filippi et al. , 2012 source
The Background states that European, UK and US guidelines recommend structural imaging when assessing suspected dementia. The paper’s Recommendations for structural MRI call for structural imaging at least once in the diagnostic work-up, and its recommendations identify frontal and temporal atrophy as findings to assess in FTD. (LLM, conf=0.91)
- Partly supportedcites Soucy et al. , 2013 sourceExperimental — accuracy not yet measured
The CCCDTD4 recommendations (Table 1; page unavailable) say structural imaging is indicated for most people with cognitive impairment, but not required for all. The “Structural neuroimaging in memory clinics” section says MRI is preferred for detecting atrophy patterns in fronto-temporal dementias. The paper therefore supports imaging as relevant to investigating these dementias, but does not establish that all major consensus guidelines recommend it specifically for bvFTD. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims · 26 with their cited sources checked
Create a free account to see all 101 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the absence of molecular biomarkers, and when combined with the syndromic overlap with other neurodegenerative disorders and psychiatric disorders, a confirmed behavioral variant frontotemporal dementia (bvFTD) diagnosis is often difficult to achieve and heavily relies on brain imaging. 6”
From MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia (2021) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to its clinical and pathological heterogeneity and symptomatic overlap with other neurodegenerative diseases, such as Alzheimer’s disease (AD), and other non-neurodegenerative psychiatric disorders, the differential diagnosis of FTD remains challenging [2, 7–9].”
From A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the differentiation between FTD and non‐neurodegenerative disorders, several CSF studies showed an excellent performance of NfL for discriminating FTD from psychiatric disorders (AUC > 0.90) 56 , 71 , 75 and consequent perceived added clinical use for the physician.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, serum NfL has the highest diagnostic accuracy with AUC of up to 0.94 for differentiating FTD from primary psychiatric disorders.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The construct of social cognition, including emotion recognition, theory of mind, empathy, and moral reasoning, has been proven difficult to measure in clinical practice. 71”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [71]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–203 of 203
Hornberger, M., Piguet, O., Kipps, C., & Hodges, J. R. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.560 · Cited by 3
Self-citationShinagawa, S., Catindig, J. A., Block, N., et al. (2016) · Figshare · doi:10.6084/m9.figshare.5128504
Correction: Advances in understanding the molecular basis of frontotemporal dementia
Rademakers, R., Neumann, M., & Mackenzie, I. R. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.76
Research works printed but not linked: 1
- Cerami, 2014, Optimized objective SPM analysis improves accuracy of [18F]FDG-PET imaging in dementia diagnosis, Eur J Neurol, 21, 303
Cited by
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
“Thus, as specified in current international recommendations 157 , measurement of NfL in CSF or blood could be used in practice for the differential diagnosis of bvFTD and PPD 158 , provided that validated thresholds could be defined.”
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citationThe use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“…encephalitis, chronic schizophrenia, alcohol related brain damage and late onset psychiatric disorders [137 – 139] may also be associated with patterns of frontal hypometabolism on FDG-PET and therefore FDG-PET should be used in combination with history and other examinations available [140 – 142].”
MethodFrontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Self-citation
Metadata
- Authors
- Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., Huey, E., Vandenbulcke, M., Masellis, M., Trieu, C., Onyike, C., Caramelli, P., de Souza, L. C., Santillo, A., Waldö, M. L., Landin-Romero, R., Piguet, O., Kelso, W., Eratne, D., Velakoulis, D., Ikeda, M., Perry, D., Pressman, P., Boeve, B., Vandenberghe, R., Mendez, M., Azuar, C., Levy, R., Le Ber, I., Baez, S., Lerner, A., Ellajosyula, R., Pasquier, F., Galimberti, D., Scarpini, E., van Swieten, J., Hornberger, M., Rosen, H., Hodges, J., Diehl-Schmid, J., & Pijnenburg, Y.
- Affiliations
- Montreal Neurological Institute and Hospital (CA)
- Amsterdam Neuroscience (NL)
- Université Laval (CA)
- The University of Sydney (AU)
- Laboratory for Translational Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium
- CERVO brain Research Centre, Laval University, Quebec, Canada
- Erasmus MC (NL)
- Columbia University (US)
- Universitair Ziekenhuis Leuven (BE)
- Sunnybrook Health Science Centre (CA)
- Johns Hopkins University (US)
- Universidade Federal de Minas Gerais (BR)
- Behavioral and Cognitive Neurology Research Group, Department of Internal Medicine, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Lund University (SE)
- Brain and Mind Centre, University of Sydney, Sydney, Australia
- The Royal Melbourne Hospital (AU)
- The University of Osaka (JP)
- University of California, San Francisco (US)
- University of Colorado Denver (US)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Pitié-Salpêtrière Hospital (FR)
- Department of Neurology, Hôpital La Pitié Salpêtrière, Paris, France
- Department of Psychology, Andes University, Bogota, Colombia
- University Hospitals of Cleveland (US)
- Manipal Hospital (IN)
- Inserm (FR)
- University of Milan (IT)
- Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands
- Department of Medicine, Norwich Medical School, Norwich, UK
- Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany
- Corresponding author
- Ducharme, Simon
- ORCID
- Ducharme, Simon
- Dols, Annemiek
- Laforce, Robert
- Devenney, Emma
- Kumfor, Fiona
- van den Stock, Jan
- Seelaar, Harro
- Gossink, Flora
- Vijverberg, Everard
- Huey, Edward
- Vandenbulcke, Mathieu
- Masellis, Mario
- Trieu, Calvin
- Onyike, Chiadi
- Caramelli, Paulo
- Santillo, Alexander
- Waldö, Maria Landqvist
- Landin-Romero, Ramon
- Piguet, Olivier
- Kelso, Wendy
- Eratne, Dhamidhu
- Velakoulis, Dennis
- Ikeda, Manabu
- Perry, David
- Pressman, Peter
- Boeve, Bradley
- Vandenberghe, Rik
- Mendez, Mario
- Lerner, Alan
- Ellajosyula, Ratnavalli
- Pasquier, Florence
- Galimberti, Daniela
- Scarpini, Elio
- Hornberger, Michael
- Rosen, Howard
- Hodges, John
- Pijnenburg, Yolande
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-04
- Volume
- 143
- Issue
- 6
- Pages
- 1632-1650
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC7849953
- OpenAlex
- W3009452141
- Cited by
- 320
- References
- 202
- Citations by year
- 2026: 39 · 2025: 53 · 2024: 64 · 2023: 56 · 2022: 57 · 2021: 43 · 2020: 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Lirias (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Fond de Recherche du Québec–Santé
- NIH
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- behavioral variant frontotemporal dementia, differential diagnosis, mental illness, delayed diagnosis, clinical evaluation, FDG-PET, neurofilament light chain, neuropsychological assessment
- MeSH terms
- Mental Disorders, Diagnosis, Differential, Female, Humans, Magnetic Resonance Imaging, Male, Neurologic Examination, Neuropsychological Tests, Fluorodeoxyglucose F18, Positron-Emission Tomography, Frontotemporal Dementia, Delayed Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.